Wednesday, November 4, 2026
Data from SEC filings, checked daily
Public filings, plainly told
Summarize with AIChatGPTClaudePerplexityGoogle AIGrokCopilot
Data updated Nov 4, 2026·New filings added every weekday·Weekly prices as of Oct 2·What changed·
Insider purchase · Form 4 · Nov 2, 2026

10% owner Arch Venture Partners XIV, L.P. buys $18 million of Aspen Neuroscience, Inc. (ASPE)

Arch Venture Partners XIV, L.P., 10% owner, bought $18 million of stock. WallStPal Score 60.

60
WallStPal ScoreHow much this purchase says, from 0 to 100. How it works

Arch Venture Partners XIV, L.P., 10% owner of Aspen Neuroscience, Inc., bought 1,200,000 shares on the open market on November 2, 2026 at an average of $15.00 a share, for a total of $18 million. The purchase was reported to the SEC on Form 4 on November 2, 2026.

It is a new position: the filing shows no shares held directly before this purchase.

1 other insider also bought at least $10,000 of ASPE within 30 days, which makes this a cluster buy.

It is Arch Venture Partners XIV, L.P.'s first purchase of ASPE in at least 1 year of our records.

In the 12 months up to this filing, Aspen Neuroscience, Inc. insiders reported 3 open-market purchases and 0 sales.

WallStPal Score: 60 out of 100, because of a brand-new position; a large purchase; first purchase in 1+ year; 1 other insider also bought.

It is too soon to say how the stock did afterward. This page will update as prices come in.

Our read

The first open-market purchase by Arch Venture Partners XIV, L.P. in our records. Insiders buy for many reasons and can be wrong; one purchase is a reason to look closer, not a reason to buy.

Source: SEC Form 4 filing ↗. This story was written automatically from the filing and weekly price data. Information, not investment advice.

Examples

We have no earlier insider purchases of Aspen Neuroscience, Inc. with a measured result to compare against, so this purchase is the first data point. Our study of 2026 insider purchases found the typical purchase roughly kept pace with the S&P 500 over three months, with a minority doing much better.

Explain it like I'm 13

Arch Venture Partners XIV, L.P. helps run Aspen Neuroscience, Inc.. Spending $18 million of their own money on the company's stock is like a coach buying a big stack of tickets to their own team's games: it suggests they think the team will do well. It is not a promise, and insiders can be wrong.

More: all ASPE insider trades · Arch Venture Partners XIV, L.P.'s track record

Sources

  1. Form 4: Arch Venture Partners XIV, L.P., purchase of ASPE · filed 2026-11-02
  2. Form 4: Arch Venture Fund X, L.P., purchase · filed 2026-11-02
  3. Form 4: Arch Venture Fund X, L.P., purchase · filed 2026-11-02

The purchase filing and the other most recent Form 4 filings for the same company.

Report an error

Tell us what looks wrong on this page. We check every report against the original filing and fix mistakes on our corrections page.

Share this trade
XTelegram
My Desk · free

Sign in to follow

Follow stocks, members of Congress, famous investors and funds, and see what's new each time you come back.